Maryland Prescription Drug Affordability Board

ANNOUNCEMENTS​

• Written Comment Request - Revised Frameworks (Posted 2/2/2026)

  In accordance with COMAR 14.01.05.06A and 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment on the revised framework documents for Ozempic and Trulicity. Comments will be accepted through close of business February 17, 2026. All comments must be submitted to [email protected]​

  • Ozempic Fram​ew​ork (Posted: 2/2/26) Version 2

  • Trulicity Fr​amework (Posted: 2/2/26) Version 2​
    

  ​
• Informational Hearing Notice: The Maryland Prescription Drug Affordability Board is evaluating its cost review study process (COMAR 14.01.04.01, et seq.) and policy review procedures (COMAR 14.01.05.01, et seq.), and invites public comment on these procedures. More information can be found here. These hearings will take place on February 10, 2026.​​​​

​

​